₹932.35
Overview of Ipca Laboratories Ltd
Shares of Ipca Laboratories Ltd fell by 9% and hit a 52-week low after the company announced plans to buy a 33.4% stake in Unichem Laboratories.
Ipca Laboratories Ltd Stock Rallies Over 20% - 22 Sep, 2023
Experts suggest short-term traders can ride the momentum by accumulating the stock for a target above Rs 1000 in 1-2 months. The stock rose from Rs 731 on June 20 to Rs 913 recorded on September 20, translating into an upside of 24% in 3 months.
Ipca Labs Acquires Additional Stake in Unichem - 21 Sep, 2023
Ipca Laboratories has acquired an additional 19.29% stake in Unichem Laboratories through an open offer for Rs 597.5 crore, taking its shareholding to 52.67%. This move follows Ipca's previous acquisition of 33.38% of Unichem at a price of Rs 402.25 per equity share.
Ipca Laboratories Stock Shows Signs of Recovery - 18 Sep, 2023
After hitting a 52-week low, Ipca Laboratories Ltd's stock has shown signs of recovery with a fresh breakout above key levels. Analysts recommend buying at Rs 925-930 for a target of Rs 1075-1080.
Ipca Labs Receives Positive Classification from USFDA - 24 Aug, 2023
Pharmaceutical company, Ipca Laboratories Ltd, reports a YoY rise in revenue and receives positive classification from the USFDA.
Ipca Laboratories' 1QFY24 Financial Performance Lower Than Expected - 23 Aug, 2023
Ipca Laboratories Ltd's 1QFY24 financial performance was lower than expected due to moderated growth in international generics, API and institutional antimalaria segments. Domestic formulation continued to perform well. FY24 earnings estimate cut by 4%. Neutral rating retained.
Ipca Labs Acquires Stake in Unichem; Net Debt Increases - 20 Aug, 2023
Ipca Laboratories Ltd acquires a 33.38% stake in Unichem for Rs 1,034.06 crore while its net debt increases over the past year.
Prabhudas Lilladher Maintains 'Hold' Rating for Ipca Laboratories - 17 Aug, 2023
Research report by Prabhudas Lilladher states that Q1 EBITDA was in line with estimates, domestic formulation business is performing well while export business outlook remains muted. FY24/FY25E EPS estimates reduced by 12%/6%. Maintain 'Hold' rating with revised TP of Rs880/share.
Long Positions Added in Pharma and Healthcare Stocks - 16 Aug, 2023
Ipca Labs, Zydus Life, and Apollo Hospitals saw the addition of long positions.
Ipca Labs Gains Maximum Share in Indian Pharma Market - 14 Aug, 2023
According to recent reports, Ipca Laboratories Ltd has gained the maximum share over the past six months in the Indian pharma market.
Ipca Laboratories Ltd: Manufacturing and Marketing Over 350 Formulations - 11 Aug, 2023
Ipca Laboratories Limited is an India-based pharmaceutical company that manufactures and markets over 350 formulations and approximately 80 active pharmaceutical ingredients (APIs) covering various therapeutic segments. Its products are sold in over 100 countries across the globe.
Ipca Laboratories to Announce Quarterly Earnings Today - 10 Aug, 2023
Investors will be keeping an eye on the quarterly earnings announcement of Ipca Laboratories Ltd.
Ipca Laboratories Ltd Shares Rise 1.09% on Unichem Acquisition - 09 Aug, 2023
Ipca Laboratories Ltd's shares are trading higher by 1.09% at Rs. 919.55 each, with a 21.71% increase in the last month after acquiring 33.38% equity in Unichem Laboratories for Rs 945 crore.
Ipca Labs to Announce Quarterly Earnings - 07 Aug, 2023
Ipca Laboratories Ltd is set to announce its quarterly earnings soon, with stock-specific action expected to continue during this period.
Ipca Acquires Stake in Unichem, Makes Open Offer - 03 Aug, 2023
Ipca Laboratories Ltd acquires a 33.38% stake in Unichem for Rs 945.35 crore and makes an open offer to acquire another 26% stake. The acquisition has failed to evoke confidence among investors.
Ipca Acquires Stake in Unichem - 02 Aug, 2023
Pharmaceutical company Ipca Laboratories Ltd acquired a 33.38% stake in Unichem Laboratories for Rs 945 crore and gained over 5% on the Nifty Mid-Cap 100.
Ipca Labs Stock Gains 3% - 31 Jul, 2023
Ipca Laboratories Ltd's stock gained 3%, and the company is currently trading in an overbought zone with an RSI of 82.61.
Ipca Laboratories' ROE Predicted to Rise Despite Being Lower Than Industry Average - 29 Jul, 2023
Despite having a lower return on equity (ROE) of 8.1% compared to the industry average of 12%, Ipca Laboratories has high earnings growth backed by its high earnings retention and heavy reinvestment of profits. The company is predicted to have an ROE of 15% in the future.
IPCA Labs Acquires Controlling Stake in Unichem Labs - 28 Jul, 2023
The Competition Commission of India has approved IPCA Labs' proposal to acquire a controlling stake in Unichem Laboratories, with a 59.38% stake purchase. Additionally, IPCA's stock crossed the 200-day SMA.
Ipca Labs Receives Approval for Acquisition of Stake in Unichem Labs - 27 Jul, 2023
The Competition Commission of India has approved Ipca Laboratories' proposed acquisition of up to a 59.3% stake in Unichem Laboratories for Rs 1,034 crore.
Source: S&P Global Market Intelligence
0.04%
Downside
Day's Volatility:0.04%
28.16%
Downside
52 Weeks Volatility:30.59%
Upside
2.43%
Returns % | |
1 Month Return | 6.67 % |
3 Month Return | 25.39 % |
1 Year Return | 0.35 % |
Market Stats | |
Previous Close | ₹935.45 |
Open | ₹932.00 |
Volume | 4.38L |
Market Cap | ₹23,732.76Cr |
Organisation | Ipca Laboratories Ltd |
Headquarters | Mumbai |
Industry | Pharmaceuticals |
E-voting on shares | Click here to vote |
Fundamentals of Ipca Laboratories Ltd
Mutual Funds have increased holdings from 29.94% to 30.27% in Jun 2023 quarter
In the last 1 year, Dr Reddys Laboratories Ltd has given 26.4% return, outperforming this stock by 26.3%
Promoters holdings remained unchanged at 46.29% of holdings in Jun 2023 quarter
In the last 3 years, Sun Pharmaceuticals Industries Ltd has given 121.5% return, outperforming this stock by 134.5%
Revenue is down for the last 3 quarters, 1.63K Cr → 1.54K Cr (in ₹), with an average decrease of 2.8% per quarter
Netprofit is down for the last 3 quarters, 143.9 Cr → 76.52 Cr (in ₹), with an average decrease of 27.1% per quarter
Foreign Institutions have decreased holdings from 10.58% to 10.05% in Jun 2023 quarter
In the last 3 years, IPCALAB stock has moved down by -13.0%
Retail Investor have decreased holdings from 9.07% to 8.48% in Jun 2023 quarter
Ipca Laboratories Ltd in the last 5 years
Lowest (18.72x)
October 10, 2019
Today (48.32x)
October 3, 2023
Industry (48.86x)
October 3, 2023
Highest (48.33x)
September 29, 2023
Funds | Holdings |
![]() | 2.45% |
![]() | 1.82% |
![]() | 3.31% |
![]() | 0.76% |
![]() | 2.33% |
Investors | Holdings % | Prev. 2 periods | 3M change |
---|---|---|---|
Promoter Holdings | 46.29% | 0.00 | |
Foreign Institutions | 10.05% | ||
Mutual Funds | 30.27% | 1.09 | |
Retail Investors | 8.48% | ||
Others | 4.92% | 19.43 |
Technicals of Ipca Laboratories Ltd share
News & Events of Ipca Laboratories Ltd
Ipca Laboratories Ltd(IPCALAB | Price |
---|---|
52 Week High | ₹955 |
52 Week Low | ₹669.8 |
Ipca Laboratories Ltd(IPCALAB | Returns |
---|---|
1 Day Returns | -3.1% |
1 Month Returns | 6.67% |
3 Month Returns | 25.39% |
1 Year Returns | 0.35% |